ATI RN
ATI Pathophysiology Final Exam
1. Medroxyprogesterone acetate (Provera) is indicated for the treatment of women with
- A. uterine bleeding.
- B. cervical cancer.
- C. ovarian cancer.
- D. fibromyalgia.
Correct answer: A
Rationale: Medroxyprogesterone acetate (Provera) is commonly used to treat conditions like abnormal uterine bleeding, amenorrhea, and endometriosis. It helps regulate the menstrual cycle and reduce excessive bleeding. Therefore, the correct answer is A. Choice B, cervical cancer, is incorrect because Provera is not indicated for the treatment of cancer. Choice C, ovarian cancer, is also incorrect as Provera is not a primary treatment for ovarian cancer. Choice D, fibromyalgia, is unrelated to the use of medroxyprogesterone acetate.
2. A patient with breast cancer is prescribed tamoxifen (Nolvadex). What critical information should the nurse provide during patient education?
- A. Tamoxifen may increase the risk of venous thromboembolism, so patients should be educated about the signs and symptoms of blood clots.
- B. Tamoxifen may decrease the risk of osteoporosis, so adequate calcium intake is important.
- C. Tamoxifen may cause weight gain, so patients should monitor their diet.
- D. Tamoxifen may increase the risk of breast cancer, so regular mammograms are essential.
Correct answer: A
Rationale: When a patient is prescribed tamoxifen, a critical piece of information that the nurse should provide during patient education is that tamoxifen may increase the risk of venous thromboembolism. Therefore, patients should be educated about the signs and symptoms of blood clots and advised to seek immediate medical attention if they occur. Choice B is incorrect because tamoxifen does not decrease the risk of osteoporosis. Choice C is incorrect as weight gain is a possible side effect of tamoxifen, but it is not a critical piece of information compared to the risk of venous thromboembolism. Choice D is incorrect because tamoxifen is actually used to treat breast cancer, not increase its risk.
3. A woman of childbearing age is diagnosed with breast cancer. She is currently taking hormonal contraceptives. What information should the woman be given regarding the hormonal contraceptives?
- A. The hormonal contraceptives do not affect the course of the disease.
- B. The hormonal contraceptives will stimulate uterine bleeding.
- C. The hormonal contraceptives will impair uterine bleeding.
- D. The hormonal contraceptives will stimulate tumor growth.
Correct answer: A
Rationale: The correct answer is A. Hormonal contraceptives should be discontinued in women diagnosed with breast cancer because they can potentially stimulate cancer growth. Choice B is incorrect as hormonal contraceptives do not stimulate uterine bleeding. Choice C is also incorrect as hormonal contraceptives typically do not impair uterine bleeding. Choice D is incorrect because hormonal contraceptives are not meant to stimulate tumor growth.
4. Which of the following describes the damage to the brain that results in cerebral palsy?
- A. Reversible with cognitive therapy in infancy
- B. Transient and resolves in adulthood through physical therapy
- C. Manifests in adulthood after regular childhood activities
- D. Irreversible and occurs before, during, or after birth or infancy
Correct answer: D
Rationale: The correct answer is D. Cerebral palsy involves irreversible damage to the brain that occurs before, during, or shortly after birth, impacting movement and coordination. Choices A, B, and C are incorrect because cerebral palsy is not reversible with cognitive therapy or physical therapy, does not resolve in adulthood, and does not manifest in adulthood after regular childhood activities.
5. What is the expected outcome of administering a granulocyte colony-stimulating factor (G-CSF)?
- A. Reduction in red blood cell count
- B. Decreased number of infections
- C. Decreased fatigue and increased energy
- D. Increase in white blood cell count
Correct answer: B
Rationale: The correct answer is B: Decreased number of infections. Granulocyte colony-stimulating factor (G-CSF) is a medication used to stimulate the production of white blood cells, specifically granulocytes, in the body. By increasing the number of white blood cells, G-CSF helps in boosting the immune system, leading to a decreased number of infections. Choice A is incorrect as G-CSF does not cause a reduction in red blood cell count. Choice C is incorrect as G-CSF primarily affects white blood cells and is not directly related to fatigue or energy levels. Choice D is incorrect as G-CSF does increase the white blood cell count but does not usually elevate it to 20,000 mm3.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access